Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: A randomized controlled trial

JAMA

Volumn 300, Issue 3, 2008, Pages 287-294

  Krab, Lianne C ^a,b   De Goede Bolder, Arja ^a   Aarsen, Femke K ^b   Pluijm, Saskia M F ^b   Bouman, Marlies J ^b   Van Der Geest, Jos N ^b   Lequin, Maarten ^b   Catsman, Coriene E ^b   Arts, Willem Frans M ^b   Kushner, Steven A ^b,c   Silva, Alcino J ^c   De Zeeuw, Chris I ^b,d   Moll, Henriëtte A ^a   Elgersma, Ype ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SIMVASTATIN;

ADOLESCENT; ARTICLE; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HAIR LOSS; HUMAN; MALE; MUSCLE WEAKNESS; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PRISM; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REY COMPLEX FIGURE TEST; SCHOOL CHILD; SCORING SYSTEM; TASK PERFORMANCE; TREATMENT DURATION; VISUOMOTOR COORDINATION;

EID: 47549111338     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.300.3.287     Document Type: Article

References (28)

1. Huson SM, Compston DA, Clark P, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in south east Wales: I, prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet. 1989;26(11):704-711.
2. Gutmann DH, Wood DL, Collins FS. Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A. 1991;88(21):9658-9662.
3. Feldmann R, Denecke J, Grenzebach M, Schuierer G, Weglage J. Neurofibromatosis type 1: motor and cognitive function and T2-weighted MRI hyperintensities. Neurology. 2003;61(12):1725-1728.
4. Krab LC, Aarsen FK, de Goede-Bolder A, et al. Impact of neurofibromatosis type 1 on school performance. J Child Neurol. 2008;23(9). doi:10.1177/0883073808316366.
5. Levine TM, Materek A, Abel J, O'Donnell M, Cutting LE. Cognitive profile of neurofibromatosis type 1. Semin Pediatr Neurol. 2006;13(1):8-20.
6. Billingsley RL, Jackson EF, Slopis JM, Swank PR, Mahankali S, Moore BD. Functional MRI of visual-spatial processing in neurofibromatosis, type I. Neuropsychologia. 2004;42(3):395-404.
7. North K, Hyman S, Barton B. Cognitive deficits in neurofibromatosis 1. J Child Neurol. 2002;17(8):605-612.
8. North K, Joy P, Yuille D, et al. Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology. 1994;44(5):878-883.
9. van Engelen SJ, Krab LC, Moll HA, et al. Quantitative differentiation between healthy and disordered brain matter in patients with neurofibromatosis type I using diffusion tensor imaging. AJNR Am J Neuroradiol. 2008;29(4):816-822.
10. Legius E, Descheemaeker MJ, Steyaert J, et al. Neurofibromatosis type 1 in childhood: correlation of MRI findings with intelligence. J Neurol Neurosurg Psychiatry. 1995;59(6):638-640.
11. Costa RM, Federov NB, Kogan JH, et al. Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1. Nature. 2002;415(6871):526-530.
12. Guilding C, McNair K, Stone TW, Morris BJ. Restored plasticity in a mouse model of neurofibromatosis type 1 via inhibition of hyperactive ERK and CREB. Eur J Neurosci. 2007;25(1):99-105.
13. Li W, Cui Y, Kushner SA, et al. The HMG-CoA reductase inhibitor lovastatin reverses the learning and attention deficits in a mouse model of neurofibromatosis type 1. Curr Biol. 2005;15(21):1961-1967.
14. Graaf MR, Richel DJ, van Noorden CJ, Guchelaar HJ. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev. 2004;30(7):609-641.
15. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A. 1992;89(14):6403-6407.
16. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation. 2002;106(17):2231-2237.
17. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis: Bethesda, Md, USA, July 13-15, 1987. Neurofibromatosis. 1988;1(3):172-178.
18. Van Haasen PP, De Bruyn EEJ, Pijl YJ, et al. Wechsler Intelligence Scale for Children-Revised (Nederlandstalige Uitgave). Lisse, the Netherlands: Swets & Zeitlinger BV; 1986.
19. Van der Geest JN, Lagers-van Haselen GC, van Hagen JM, et al. Visual depth processing in Williams-Beuren syndrome. Exp Brain Res. 2005;166(2):200-209.
20. Baizer JS, Kralj-Hans I, Glickstein M. Cerebellar lesions and prism adaptation in macaque monkeys. J Neurophysiol. 1999;81(4):1960-1965.
21. Pisella L, Rossetti Y, Michel C, et al. Ipsidirectional impairment of prism adaptation after unilateral lesion of anterior cerebellum. Neurology. 2005;65(1):150-152.
22. Lezak MD, Howieson DB, Loring DW, Hannay HJ, Fischer JS. Neuropsychological Assessment. 4th ed. New York, NY: Oxford University Press; 2004.
23. Medicines Evaluation Board. Summary of Product Characteristics: ZCR-T-082004. The Hague, the Netherlands: Medicines Evaluation Board; 2005.
24. Descheemaeker MJ, Ghesquiere P, Symons H, Fryns JP, Legius E. Behavioural, academic and neuropsychological profile of normally gifted neurofibromatosis type 1 children. J Intellect Disabil Res. 2005;49(pt 1):33-46.
25. Rapport LJ, Brines DB, Axelrod BN, Theisen ME. Full scale IQ as mediator of practice effects: the rich get richer. Clin Neuropsychol. 1997;11(4):375-380.
26. Struiksma AJM, Van Der Leij A, Vieijra JPM. Diagnostics Tool of Technical Reading and Basic Spelling (Dutch version). Amsterdam, the Netherlands: VU Publisher; 2004.
27. Ruijssenaars AJJM, Van Lieshout ECDM, Van Luit JEH. Mathematical Problems and Dyscalculia (Dutch version). Rotterdam, the Netherlands: Lemniscaat Publisher; 2004.
28. Brown RT, Amler RW, Freeman WS, et al. Treatment of attention-deficit/ hyperactivity disorder: overview of the evidence. Pediatrics. 2005;115(6):e749-e757.